Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 322 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Vancomycin hydrochloride Clear all

Conditions: Wound Infection
Interventions: Vancomycin Powder; Drug
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years to 90 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Wound Infection, Abscess, Systemic Inflammation, Cellulitis
Interventions: Single-Dose IV Oritavancin Diphosphate, IV Vancomycin, Placebo; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 968 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Primary Sclerosing Cholangitis, Post- Orthotopic Liver Transplantation
Interventions: Vancomycin; Drug
Lead sponsor: Ochsner Health System; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Primary Sclerosing Cholangitis, Inflammatory Bowel Disease
Interventions: Vancomycin; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Bacterial Infections
Interventions: BestDose Computer Software; Device
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: Not listed
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Primary Total Knee Arthroplasty, Intraosseous Morphine Injection, Knee Osteoarthritis
Interventions: Morphine, Vancomycin; Drug
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: C. Difficile, Diarrhea, Enterocolitis
Interventions: Fidaxomicin, Metronidazole, Vancomycin; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Clostridium, Difficile, Fidaxomicin, Vancomycin
Interventions: Fidaxomicin, Vancomycin with Taper/Pulse, Vancomycin; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 32
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 28 more

Conditions: Skin Diseases, Bacterial
Interventions: Tigecycline, ampicillin-sulbactam; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 31
States / cities: Scottsdale, Arizona • Jonesboro, Arkansas • Chula Vista, California + 27 more

Conditions: Large B Cell Lymphoma, Non Hodgkin Lymphoma (NHL), Diffuse Large B Cell Lymphoma (DLBCL), Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B Cell Lymphoma Relapsed
Interventions: Vancomycin 125mg, Radiation Therapy, CAR-T; Drug · Radiation · Biological
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Multidrug Resistant Bacterial Infection, Enterobacteriaceae Infections, Pseudomonas Aeruginosa, VRE Infection, Methicillin-resistant Staphylococcus Aureus
Interventions: PMT; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Atlanta, Georgia • St Louis, Missouri • Philadelphia, Pennsylvania

Conditions: Clostridium Infections
Interventions: Nitazoxanide, Vancomycin; Drug
Lead sponsor: Romark Laboratories L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 10
States / cities: Torrance, California • Bay Pines, Florida • Atlanta, Georgia + 6 more

Conditions: Group B Streptococcal Infection
Interventions: Vaginal and rectovaginal swab cultures; Biological
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Cincinnati, Ohio

Conditions: Surgical Site Infection
Interventions: Vancomycin powder; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Staphylococcal Bacteraemia
Interventions: Cefazolin, Dalbavancin, Daptomycin, Nafcillin, Oxacillin, Vancomycin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 23
States / cities: Birmingham, Alabama • Sacramento, California • Torrance, California + 19 more

Conditions: Sepsis
Interventions: personalized dosing adjustment of vancomycin; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 1 Month to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Anti-biotic Resistance
Interventions: VSL#3, sugar pill (placebo); Dietary Supplement
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Abscess, Wound Infection, Surgical Site Infection, Cellulitis
Interventions: IV Dalbavancin, Vancomycin/Linezolid; Drug
Lead sponsor: Durata Therapeutics Inc., an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 739 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 30
States / cities: Montgomery, Alabama • Anaheim, California • Buena Park, California + 26 more

Conditions: Critical Limb Ischemia
Interventions: Cord blood stem cell injection; Biological
Lead sponsor: Richard Burt, MD; Other
Eligibility: 18 Years to 72 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Clostridium Difficile Infection
Interventions: Cadazolid, Vancomycin, Placebo-matching cadazolid, Placebo-matching vancomycin; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 11
States / cities: Newark, Delaware • Jacksonville, Florida • Orlando, Florida + 8 more

Conditions: Pre-Diabetes
Interventions: Vancomycin, Placebo, Neomycin, Clindamycin, Fecal Microbiota Transplantation; Drug · Other · Procedure
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Cirrhosis, Hepatic Encephalopathy
Interventions: Placebo, VE303, oral vancomycin; Drug
Lead sponsor: Patricia Bloom; Other
Eligibility: 18 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Fractures, Open, Wounds and Injuries--Infections, Anti-Bacterial Agents, Fractures, Bone, Extremity Fracture Lower, Extremity Fractures Upper
Interventions: Vancomycin, Tobramycin; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Aurora, Colorado • Denver, Colorado

Conditions: Ulcerative Colitis
Interventions: Fecal Microbiota Transplantation (FMT), OpenBiome, pretreatment antibiotics; Biological · Other
Lead sponsor: Najwa Elnachef; Other
Eligibility: 18 Years to 64 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Vancomycin in Spine Surgery

Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)

Vancomycin Treatment in Recurrent PSC in Liver Transplant Patients

A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis

Prospective Study to Optimize Vancomycin Dosing in Children and Adults Using Computer Software

Effectiveness of Adding Morphine to Intraosseous Vancomycin for Pain Control in Total Knee Arthroplasty

Impact of Oral Antibiotic Treatment on C. Difficile

Optimal Treatment for Recurrent Clostridium Difficile

Study Comparing the Safety and Efficacy of Tigecycline With Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Skin Infections

Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas

PMT for MDRO Decolonization

Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease

Intrapartum Effect of Vancomycin on Rectovaginal GBS Colonization

Comparative Effectiveness and Cost-Benefit Analysis of Vancomycin Powder in High Risk Spine Surgery Patients

DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia

Vancomycin and Acute Kidney Injury in Sepsis Treatment - Intervention

A Pilot Trial to Determine the Efficacy of VSL#3 for Reducing Colonization by VRE

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Efficacy and Safety of Umbilical Cord Blood Injection for Critical Limb Ischemia

Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)

Interventional Bioremediation of Microbiota in Metabolic Syndrome

VE303 for Treatment of Hepatic Encephalopathy (HE)

Acute Application of Antibiotic Powder in Open Fracture Wounds

Optimal Fecal Microbiota Transplant Dosing for Mild to Moderate Ulcerative Colitis